{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0"}]}],"title":"Complete response (CR)"},{"categories":[{"measurements":[{"groupId":"OG000","value":"1"}]}],"title":"Partial response (PR)"},{"categories":[{"measurements":[{"groupId":"OG000","value":"1"}]}],"title":"Overall response rate (ORR)"}],"denoms":[{"counts":[{"groupId":"OG000","value":"80"}],"units":"Participants"}],"description":"Overall Response (OR) of Partial Response (PR) or greater based on local investigator assessment. For patients with solid tumors, the assessment criteria will be RECIST 1.1 and will include responses of CR and/or PR. For hematologic tumors other appropriate hematological response criteria will apply and are included in the appendices. ORR: CR+PR","groups":[{"description":"Dovitinib (TKI) will be dosed on a flat scale of 500 mg on a 5 days on/2 days off dosing schedule.","id":"OG000","title":"TKI258"}],"paramType":"NUMBER","populationDescription":"Full Analysis Set (FAS) included all patients who received at least one dose of study drug.\n\nFAS was used for the analysis of efficacy endpoints.","reportingStatus":"POSTED","timeFrame":"Week 16","title":"Overall Response (OR) of Partial Response (PR) or Greater","type":"SECONDARY","unitOfMeasure":"number of participants"}